topotecan has been researched along with Neoplasms in 224 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 63 (28.13) | 18.2507 |
| 2000's | 87 (38.84) | 29.6817 |
| 2010's | 60 (26.79) | 24.3611 |
| 2020's | 14 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Ferguson, DM; Flatten, KS; Gálvez-Peralta, M; Hackbarth, JS; Hiasa, H; Kaufmann, SH; Xing, C | 1 |
| Chen, XG; Chern, JW; Guo, QL; He, XG; Huang, CH; Li, TK; Li, ZY; Wang, XJ; Yang, Q; You, QD | 1 |
| Chen, YL; Cheng, CM; Chung, KY; Hsu, CY; Huang, KS; Kao, CL; Tseng, CH; Tzeng, CC | 1 |
| Choi, HK; Lee, K; Xia, Y | 1 |
| Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL | 1 |
| Benetti, E; Centamore, A; Collina, S; Della Volpe, S; Martino, E; Sakaj, M; Sala, A; Terribile, E | 1 |
| Chen, HL; Cheng, PL; Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Yang, GZ; Yang, QR; Zhang, N; Zhang, XS; Zhu, GX | 1 |
| Jing, Y; Ojima, I; Wang, C; Wang, X | 1 |
| Chen, J; Hou, T; Huang, Y; Li, M; Li, X; Liu, F; Ni, J; Pan, P; Sun, H; Tian, S; Wang, X; Yu, H; Zhao, JJ; Zhu, F | 1 |
| Agama, K; An, LK; Hu, DX; Pommier, Y; Tang, WL; Wang, W; Yang, H; Zhang, Y | 1 |
| Alonso, C; Martín-Encinas, E; Palacios, F; Selas, A | 1 |
| Ishii, KJ; Ishiura, M; Kashiwakura, JI; Kawai, T; Kitai, Y; Maemoto, T; Maenaka, K; Matsuda, T; Muromoto, R; Shoji, H; Tadokoro, T; Takahashi, R; Yamada, S | 1 |
| Kitai, Y | 1 |
| Coussens, NP; Dexheimer, TS; Doroshow, JH; Morris, J; Silvers, T; Teicher, BA; Wright, J | 1 |
| Li, H; Sui, S; Wang, L; Xu, S; Zhang, L; Zhang, X; Zheng, X | 1 |
| Chao, Y; Hsu, KM; Huang, YH; Kang, YM; Lan, A; Lan, KL | 1 |
| Chan, JV; Cheok, CF; Chng, WJ; Goh, BC; Hung, HT; Kannan, S; Koh, LYJ; Kong, LR; Lane, DP; Lau, JA; Le, TBU; Lee, M; Lim, CM; Mohamed Salleh, NAB; Ong, RW; Periyasamy, G; Tan, TZ; Thangavelu, M; Venkitaraman, A; Verma, CS; Wang, L | 1 |
| Jain, A; Jain, SK; Saraf, S; Tiwari, A; Verma, A | 1 |
| Bean, S; Carter, BW; Colen, R; Gong, J; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Ogbonna, DC; Pant, S; Piha-Paul, SA; Shah, J; Subbiah, V; Thein, KZ; Tsimberidou, A; Zarifa, A | 1 |
| Chung, Y; Jeon, I; Kang, CY; Kim, BS; Koh, CH; Lee, JM; Park, MH; Shin, KS; Song, B | 1 |
| He, S; Li, Y; Lu, G; Pan, Y; Ren, M; Wu, K; Zhang, Z; Zhao, Y | 1 |
| Hsu, CW; Huang, R; Li, S; Sakamuru, S; Xia, M; Zou, C | 1 |
| Zou, L | 1 |
| Amrahli, M; Centelles, MN; Gedroyc, W; Miller, AD; So, PW; Stebbing, J; Thanou, M; Wright, M; Xu, XY | 1 |
| Doles, JD; Hogan, KA; Huston, O; Jatoi, A; O'Connor, J; Wahner Hendrickson, AE | 1 |
| Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR | 1 |
| Chang, A; Chen, P; Chiao, PJ; Hu, Y; Huang, P; Jiang, W; Ling, J; Liu, K; Lu, W; Song, M; Sun, Y | 1 |
| Lopes-de-Araújo, J; Nunes, C; Reis, S | 1 |
| Belani, C; Cristea, MC; Gandara, DR; Gitlitz, BJ; Goldkorn, A; Gong, IY; Groshen, SG; Kelly, K; Koczywas, M; Liu, SV; Newman, EM; Reckamp, KL; Semrad, TJ; Synold, TW; Xu, T; Xu, Y | 1 |
| Han, HK; Lee, SH; Lee, YS; Song, JG | 1 |
| Gajjar, A; Mitchell, AB; Santana, VM; Stewart, CF; Vasilyeva, A | 1 |
| Castellano, G; Torrens, F | 1 |
| Dhagat, S; Eswari, JS; Yadav, M | 1 |
| Qing, L; Qing, W | 1 |
| Pommier, Y; Thomas, A | 1 |
| Patel, KJ; Tannock, IF; Trédan, O | 1 |
| Du, P; Gui, L; Han, X; Li, N; Shen, Y; Shi, Y; Song, Y; Sun, Y; Wang, J; Wang, S; Yang, J | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Blakely, LJ; Schwartzberg, LS; Smiley, LM; Stewart, CF; Tagen, M; Tauer, KW | 1 |
| Chen, WH; Lei, Q; Liu, Y; Luo, GF; Zhang, XZ; Zhuo, RX | 1 |
| Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L | 1 |
| Bai, Y; Ma, S; Shen, B; Yuan, D; Zhao, K | 1 |
| Bang, YJ; Beijnen, JH; Chung, HC; Dar, MM; Devriese, LA; Huitema, AD; Lewis, LD; Mendelson, DS; Mergui-Roelvink, M; Schellens, JH; Smith, DA; Voest, EE; Witteveen, PE | 1 |
| Arakawa, Y | 1 |
| de Jong, J; Neefjes, J; Pang, B; Qiao, X; Wessels, LF | 1 |
| Gjerset, RA; Zhao, M | 1 |
| Gad, Y; Helgason, T; Hong, DS; Jain, RK; Kurzrock, R; Naing, A; Shi, NY; Wheler, J | 1 |
| Iqbal, Z; Khar, RK; Khuroo, T; Mirza, MA; Padhi, S; Panda, AK; Talegaonkar, S; Verma, D | 1 |
| Allen, D; Beumer, JH; Bonner, WM; Chen, A; Collins, J; Covey, JM; Doroshow, JH; Eiseman, JL; Gutierrez, M; Holleran, JL; Ji, J; Kinders, RJ; Kummar, S; Parchment, R; Pfister, TD; Pommier, Y; Redon, C; Rubinstein, L; Tomaszewski, J; Wang, L; Yutzy, W; Zhang, Y | 1 |
| Allen, S; DuBois, SG; Gustafson, WC; Hollinger, F; Karski, EE; Long-Boyle, JR; Matthay, KK; Nasholm, NM; Shiboski, S; Vo, KT | 1 |
| Bracher, F; Tremmel, T | 1 |
| Hurkat, P; Jain, A; Jain, SK; Saraf, S | 1 |
| Akira, S; Ishii, KJ; Kawai, T; Kawasaki, T; Kitai, Y; Kobiyama, K; Matsuda, T; Sueyoshi, T; Zou, J | 1 |
| Barbuti, AM; Chen, ZS; Wang, YJ; Wen, AW; Wurpel, JND; Yu, XY; Zhang, GN; Zhang, YK; Zhu, XJ | 1 |
| Hollingshead, MG | 1 |
| Animati, F; Beijnen, JH; Capriati, A; Crea, A; Schellens, JH; van den Heuvel, IJ; Veltkamp, SA; Voest, EE; Voogel-Fuchs, M; Witteveen, EO | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Hong, WK; Khuri, FR; Kim, ES; Lee, JJ; Lee, JL; Lippman, SM; Liu, S; Shin, DM; William, WN | 1 |
| Chen, ZS; Dai, CL; Fu, LW; Liang, YJ; Tiwari, AK; Tong, XZ; Wang, F; Wang, YS; Yan, YY | 1 |
| Beijnen, JH; Burris, H; Cohen, RB; Dar, MM; Goel, S; Kurian, S; Lewis, LD; Loftiss, J; Oostendorp, RL; Patnaik, A; Rosing, H; Smith, DA; Voest, EE; Witteveen, PO | 1 |
| Beijnen, JH; Boss, DS; Pluim, D; Rosing, H; Schellens, JH; Siegel-Lakhai, WS; Ten Bokkel Huinink, WW; van Egmond-Schoemaker, NE | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Borad, MJ; Curtis, KK; Fitch, TR; Griffin, PP; Hartney, JT; Jewell, RC; Lebowitz, PF; Northfelt, DW; Park, JW | 1 |
| Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, RB; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Watkins, A | 1 |
| Aerts, I; Chastagner, P; Chatelut, E; Corradini, N; Dias, N; Djafari, L; Frappaz, D; Gentet, JC; Geoerger, B; Landman-Parker, J; Le Deley, MC; Leblond, P; Ndiaye, A; Paci, A; Pasquet, M; Rubie, H; Schmitt, A; Vassal, G | 1 |
| Bekaii-Saab, T; Kraut, EH; Serna, DS | 1 |
| Barenholz, Y; Zucker, D | 1 |
| Burris, HA; Greco, FA; Infante, JR; Jewell, RC; Jones, SF; Spigel, DR; Thompson, DS | 1 |
| Azrak, RG; Rempinski, DR; Rustum, YM; Saifo, MS | 1 |
| Glimelius, B; Lahn, M | 1 |
| Carmichael, J; Cassidy, J; Macpherson, E; Ranson, M; Samol, J; Scott, E; Thomas, A | 1 |
| Adams, S; Alagkiozidis, I; Benencia, F; Carpenito, C; Coukos, G; Facciabene, A; Jonak, Z; June, CH; Powell, DJ; Tsiatas, M | 1 |
| Czyz, M; Duechler, M; Wilczynski, J | 1 |
| Allen, D; Chen, X; Choyke, P; Doroshow, JH; Figg, WD; Horneffer, Y; Juwara, L; Kummar, S; Melillo, G; Murgo, AJ; Raffeld, M; Rapisarda, A; Spencer, SD; Steinberg, SM; Strassberger, A; Turkbey, IB | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
| Ames, M; Bonner, W; Carter, J; Chen, A; Doroshow, JH; Hollingshead, M; Ji, J; Jia, L; Kinders, R; Kummar, S; Melillo, G; Murgo, AJ; Parchment, RE; Pommier, Y; Reid, JM; Rubinstein, L; Speranza, G; Stotler, H; Tomaszewski, JE; Wang, L; Weil, M; Zhang, Y | 1 |
| Dawson, JL; Field, TL; Fields, KK; Goldstein, SC; Kim, J; Lush, RM; Maddox, BL; Neuger, AM; Partyka, JS; Perkins, JB; Simonelli, CE; Sullivan, DM | 1 |
| Dai, NT; Flatten, KS; Kaufmann, SH; McDonald, JS; Patel, AG; Poirier, GG; Schneider, PA | 1 |
| Cui, J; Li, C; Wang, C; Wei, N; Yang, H; Zhao, X | 1 |
| Jafari, M; Kislukhin, G; Long, AD; Murphy, ML | 1 |
| Barfield, RC; Bowman, LC; Hale, GA; Handgretinger, R; Horwitz, EM; Kasow, KA; Leung, W; Li, C; Srivastava, DK; Stewart, CF; Wright, NL | 1 |
| Cho, K; Joo, SW; Kim, M; Lee, SY; Ock, K | 1 |
| Borgel, S; Carter, J; Divelbiss, R; Doroshow, JH; Evrard, YA; Hollingshead, M; Ji, J; Khin, SA; Kinders, RJ; Kummar, S; Parchment, RE; Pfister, TD; Pommier, Y; Stotler, H; Tomaszewski, JE; Zhang, Y | 1 |
| Fukuoka, M; Furuse, K; Hasegawa, K; Hino, M; Horikoshi, N; Kanamaru, R; Kimura, I; Kinoshita, H; Kobayashi, K; Niitani, H; Noda, K; Taguchi, T; Takeuchi, K; Yoneda, S | 1 |
| Beijnen, JH; Dubbelman, R; Hearn, S; Herben, VM; Rosing, H; Schellens, JH; Schoemaker, nE; ten Bokkel Huinink, WW; van Zomeren, DM | 1 |
| Chang, FH; Cheng, WF; Hong, K; Hong, RL; Liu, JJ; Tseng, YL | 1 |
| Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Devereux, L; Goldberg, J; Grana, G; Hageboutros, A; Khatri, J; Rodman, WD; Sbar, EI; Tritschler, L | 1 |
| Goldwasser, F; Gross-Goupil, M; Hasbini, A; Lokiec, F; Lopez, G; Misset, JL; Romain, D; Tigaud, JM | 1 |
| Glomme, S; Hertig, J; Hess, CF; Pradier, O; Rave-Fränk, M; Schmidberger, H; Virsik-Köpp, P; Weiss, E | 1 |
| Gajjar, A; Houghton, PJ; Kirstein, MN; Liu, T; Santana, VM; Stewart, CF; Tan, M; Zamboni, WC | 1 |
| Gelderblom, H; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; van Boven-van Zomeren, DM; Verweij, J | 1 |
| Desai, SD; Gounder, MK; Liu, LF; Rodriguez-Bauman, A; Rubin, EH; Wu, X; Yang, JM; Zhang, H | 1 |
| Douillard, JY; Schiller, J | 1 |
| Dropcho, S; Fife, K; Hanna, N; Seitz, DE; Sweeney, C | 1 |
| Bailly, C; Lansiaux, A | 1 |
| de Jonge, MJ; Gelderblom, H; Loos, WJ; Soepenberg, O; Sparreboom, A; van Boven-van Zomeren, DM; Verweij, J | 1 |
| Aisner, J; Beers, S; Locsin, S; Musanti, R; Rubin, EH; Smith, S | 1 |
| Contra, T; Díaz Pérez, MA; Madero López, L; Pérez Martínez, A; Scaglione, C | 1 |
| Canal, P; Chatelut, E; Delord, JP | 1 |
| Benson, A; Poplin, E; Vergote, I | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Adams, JR; Armitage, JO; Bennett, CL; Demetri, GD; Elting, LS; George, JN; Lembersky, BC; Lyman, GH | 1 |
| Aquino, VM; Bash, RO; Bowers, DC; Haynes, HJ; Journeycake, JM; Leavey, PJ; Mulne, AF; Tomlinson, G; Winick, NJ | 1 |
| Daw, NC; Furman, WL; Gajjar, AJ; Hawkins, DR; Houghton, PJ; Iacono, LC; Panetta, JC; Santana, VM; Stewart, CF | 1 |
| Glisson, BS; Lee, JS; Palmer, JL; Shin, DM; Tsao, AS | 1 |
| Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE | 1 |
| Ivanova, A; Wang, K | 1 |
| Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA | 1 |
| Adams, N; Cunningham, CC; MacEachern, JB; Nemunaitis, J; Paulson, AS; Rich, D; Ruxer, RL; Vukelja, S | 1 |
| Delgrosso, A; Freda, T; Hamilton, J; Posey, JA; Wang, H; Zamboni, WC; Zhang, R | 1 |
| Briasoulis, E; Karavassilis, V; Mauri, D; Pavlidis, N; Pentheroudakis, G; Rammou, D; Tzamakou, E | 1 |
| Elenius, K; Hietanen, S; Holmström, T; Johnson, RS; Junttila, TT; Koivusalo, R; Mialon, A; Papageorgiou, AC; Sankinen, M; Söderström, H; Westermarck, J | 1 |
| Appleman, LJ; Campos, SM; Clark, JW; Eder, JP; Fuller, AF; Goodman, A; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV | 1 |
| Cain, A; Crews, KR; Daw, NC; Furman, W; Houghton, PH; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tan, M | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Garber, K | 1 |
| Eklund, JW; Mulcahy, MF; Trifilio, S | 1 |
| Adams, N; Barrera, D; Cunningham, C; Graham, S; Nemunaitis, J; Nugent, J; Senzer, N; Stewart, C | 1 |
| Belozerov, VE; Van Meir, EG | 1 |
| Brown, LM; Cowen, RL; Debray, C; Erler, JT; Eustace, A; Parker, CA; Sheppard, FC; Stratford, IJ; Williams, KJ | 1 |
| Angerson, WJ; Boyd, M; Clark, AM; Cosimo, E; Gaze, MN; Mairs, RJ; McCluskey, AG; Ross, SC | 1 |
| Burnett, A; Edwards, S; Facio, G; Garcia, AA; Muderspach, L; O'meara, A; Roman, L | 1 |
| Alberti, D; Arzoomanian, R; Binger, K; Dubey, S; Feierabend, C; Hutson, P; Schiller, JH; Volkman, J; Wilding, G | 1 |
| Hochster, H; Kosloff, R; Liebes, L; Muggia, F | 1 |
| Armand, JP; Djafari, L; Djazouli, K; Faivre, S; Ghesquières, H; Lhommé, C; Lozahic, S; Pautier, P; Raymond, E | 1 |
| Martin, S | 1 |
| Eid, A; Galun, E; Gelman, AE; Olthoff, KM; Shaked, A; Zamir, G; Zeira, E | 1 |
| Hardwick, LJ; van Veen, HW; Velamakanni, S | 1 |
| Beijnen, JH; Jewell, RC; Kuppens, IE; Mangum, SG; Paul, EM; Radema, SA; Schellens, JH; Voest, EE; Witteveen, EO | 1 |
| Adams, GP; Drummond, DC; Hayes, ME; Kirpotin, DB; Marks, JD; Zhou, Y; Zou, H | 1 |
| Freeman, BB; Gajjar, A; Iacono, LC; Panetta, JC; Santana, VM; Schaiquevich, P; Stewart, CF | 1 |
| Albayrak, M; Apan, A; Bayar Muluk, N; Bülbül Hizel, S; Ozyazici, A; Sanli, C | 1 |
| Bonneterre, J | 1 |
| Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Beijnen, JH; Davies, BE; Koier, I; Maes, RA; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Arbuck, SG; Cheson, BD; Phillips, PH | 1 |
| Barbosa, K; Niedzwiecki, D; Saltz, L; Sirott, M; Tao, Y; Tong, W; Trochanowski, B; Tzy-Jyun, Y; Wright, P; Young, C | 1 |
| Sinha, BK | 1 |
| Schellens, JH; Verweij, J | 1 |
| Beijnen, JH; Davies, BE; de Boer-Dennert, M; Maes, RA; Rosing, H; Schellens, JH; van Warmerdam, LJ; Verweij, J | 1 |
| Awada, A; Burris, HA; Cobb, PW; Eckardt, JR; Fields, S; Kuhn, JG; Rinaldi, DA; Smith, L; Von Hoff, DD | 1 |
| Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD | 1 |
| Frucht, H; Goosenberg, E; Haas, NB; Halbherr, T; LaCreta, FP; O'Dwyer, PJ; Yao, KS | 1 |
| Baker, SD; Crom, WR; Heideman, RL; Jones, D; Pratt, CB; Stewart, CF | 1 |
| Brennan, JM; Haas, NB; Hudes, GR; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Walczak, J | 1 |
| Bowman, L; Furman, W; Heideman, R; Kuttesch, JF; Marina, N; Ochs, J; Pratt, CB; Sandlund, JT; Santana, VM; Stewart, C | 1 |
| Chachoua, A; Hochster, H; Liebes, L; Oratz, R; Raphael, B; Sorich, J; Speyer, J; Taubes, B; Vinci, RZ; Wernz, J | 1 |
| Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P | 1 |
| Beijnen, J; de Boer-Dennert, M; Hansen, H; Koier, I; Lund, B; Planting, A; Rosing, H; Verweij, J | 1 |
| Creemers, GJ; Lund, B; Verweij, J | 1 |
| Furue, H | 1 |
| Arbuck, SG; Cheson, BD | 1 |
| Ames, MM; Balis, FM; Blaney, SM; Cole, DE; Craig, C; Hammond, D; Krailo, M; Poplack, DG; Reaman, G; Reid, JM | 1 |
| Donehower, RC; Slichenmyer, WJ | 1 |
| Bowling, MK; Donehower, RC; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE | 1 |
| Dancey, J; Eisenhauer, EA | 1 |
| Crom, WR; Furman, WL; Gajjar, A; Heideman, RL; Houghton, PJ; Meyer, WH; Pratt, CB; Stewart, CF; Zamboni, WC | 1 |
| Bell, B; Dryer, ZA; Grier, H; Kurtzberg, J; Pratt, CB; Santana, VM; Stewart, CF; Tubergen, DG; Vietti, TJ; Winick, N; Zamboni, WC | 1 |
| Boothman, DA; Kinsella, TJ; Lamond, JP; Wang, M | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; O'Reilly, S; Rowinsky, EK; Sartorius, S; Slichenmyer, W | 1 |
| Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE | 1 |
| Mani, S; Ratain, MJ | 1 |
| Anderson, S; Beidler, D; Belliveau, D; Burtness, BA; Cheng, YC; Fedele, J; Flynn, SD; Murren, JR; Pizzorno, G; Tocino, I; Zelterman, D | 1 |
| Burris, HA; Muggia, FM | 1 |
| Broom, C; Burris, HA; Creemers, GJ; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; Verweij, J; Von Hoff, DD | 1 |
| Heuser, A; Sauer, R | 1 |
| Berger, NA; Whitacre, CM | 1 |
| Csóka, K; Dhar, S; Fridborg, H; Jonsson, E; Larsson, R; Nygren, P; Sundström, C | 1 |
| de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Arbuck, SG; Takimoto, CH | 2 |
| Kaye, SB; Vasey, PA | 1 |
| Beijnen, JH; Dubbelman, AC; Groot, Y; Herben, VM; Mandjes, IA; ten Bokkel Huinink, WW; van Gortel-van Zomeren, DM | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Bleyer, WA; Gillespie, A; Krailo, MD; Needle, MN; Poplack, DG; Reaman, GH; Sato, JK | 1 |
| Arbuck, SG; Kieffer, LV; Takimoto, CH | 1 |
| Burris, H; Eckardt, JR; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van der Burg, ME; Verweij, J; Von Hoff, DD | 1 |
| Boland, I; Cappelli, C; Gouyette, A; Imadalou, K; Lucchi, E; Morizet, J; Pein, F; Pondarré, C; Santos, A; Thomas, C; Vassal, G | 1 |
| Burris, HA; Eckardt, JR; Eckhardt, SG; Ganapathi, R; Hammond, LA; Hodges, S; Kuhn, JG; Rodriguez, GA; Rothenberg, ML; Rowinsky, EK; Von Hoff, DD; Weiss, GR | 1 |
| Batist, G; Bernard, S; Egorin, MJ; Hollis, DR; Lilenbaum, RC; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Brewster, LR; Cowan, KH; Goldspiel, B; Gossard, MR; Gress, R; Hakim, F; Myhand, RC; Noone, MH; O'Shaughnessy, JA; Schneider, E; Tolcher, AW; Weiss, RB; Zujewski, J | 1 |
| Blum, RH; Chachoua, A; Hochster, H; Liebes, L; Oratz, R; Sorich, J; Speyer, J; Taubes, B; Wernz, J; Zeleniuch-Jacquotte, A | 1 |
| Abbruzzese, JL; Ellis, AL; Hess, KR; Loughlin, S; Madden, T; Newman, RA; Raber, MN; Sugarman, SM; Zwelling, LA | 1 |
| Fridborg, H; Jonsson, E; Larsson, R; Nygren, P | 1 |
| Burris, H; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van den Burg, ME; Verweij, J; von Hoff, DD | 1 |
| Cersosimo, RJ | 1 |
| Muggia, FM; O'Leary, J | 1 |
| Burris, H; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van der Burg, ME; Verweij, J; Von Hoff, DD | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Morrissey, LH | 1 |
| Bowman, LC; Gajjar, AJ; Heideman, RL; Houghton, PJ; Meyer, WH; Pappo, AS; Pratt, CB; Santana, VM; Stewart, CF; Tan, M; Zamboni, WC | 1 |
| Beijnen, JH; Bult, A; Doyle, E; Rosing, H; Schellens, JH; ten Bokkel, WW; van Zomeren, DM | 1 |
| Chen, AY; Choy, H; Rothenberg, ML | 1 |
| Harstrick, A; Hilger, RA; Klaassen, U; Lindtner, B; Müller, MR; Rustum, YM; Schleucher, N; Seeber, S; Vanhoefer, U | 1 |
| de Jonge, MJ; Gelderblom, H; Loos, WJ; Sparreboom, A; Verweij, J | 2 |
| Brouwer, E; de Jonge, MJ; Doyle, E; Gelderblom, H; Hearn, S; Loos, WJ; Mantel, MA; Planting, AS; Ross, G; Sparreboom, A; van Beurden, V; van der Burg, ME; Verweij, J | 1 |
| Baker, SD; Gallo, JM; Grochow, LB; Laub, PB; Rowinsky, EK | 1 |
| Abad, A; Guillot, M; Martin, C; Plasencia, C; Taron, M | 1 |
| De Cesare, M; Pace, S; Pisano, C; Pratesi, G; Zunino, F | 1 |
| Brooks, SE; Day, RS; Dobson, JM; Doyle, LA; Egorin, MJ; Meisenberg, BR; Nemieboka, NN; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Akhtar, S; Beckman, RA; Doyle, E; Fields, SZ; Mould, DR; Wright, J | 1 |
| Furman, W; Houghton, PJ; Radomski, K; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
| Dhar, S; Graf, W; Jonsson, B; Jonsson, E; Larsson, R; Nygren, P | 1 |
| Brouwer, E; de Jonge, MJ; Gelderblom, AJ; Hearn, S; Loos, WJ; Ouwens, L; Planting, AS; Sparreboom, A; van der Burg, ME; Verheij, C; Verweij, J | 1 |
| Brouwer, E; de Jonge, MJ; Gelderblom, HJ; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Doyle, LA; Edelman, MJ; Egorin, MJ; Hausner, PF; Meisenberg, BR; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Adams, AL; Boente, M; Bookman, MA; Ciccotto, S; Gallo, JM; Millenson, MM; Ozols, RF; Padavic-Shallers, K; Rogatko, A; Rogers, B; Rosenblum, N; Schilder, RJ; Weiner, LM | 1 |
| Cantrell, CL; Dunleavy, TL; Dunphy, FR; Harrison, BR; Petruska, PJ; Pincus, SM; Richart, JM; Visconti, JL | 1 |
| Algazy, K; Gallagher, M; Giantonio, B; Haller, D; O'Dwyer, PJ; Raskay, BJ; Stevenson, JP; Sun, W; Vaughn, D | 1 |
| Lokich, J | 1 |
| Bernstein, ML; Harris, MB; Hayashi, R; Kepner, JL; Saylors, RL; Stine, KC; Sullivan, J; Vietti , TJ; Wall, DA | 1 |
| D'Argenio, DZ; Delauter, BJ; Egorin, MJ; Farese, AM; Kubat, NM; MacVittie, T; Potter, DM; Stewart, CF; Tubergen, D; Zamboni, WC | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N | 1 |
| Berg, SL; Blaney, SM; Bomgaars, L | 1 |
| Athale, UH; Gajjar, A; Heideman, RL; Kuttesch, JF; Meyer, W; Moghrabi, A; Pratt, C; Stewart, C | 1 |
| Bamberg, M; Herskind, C; Ohneseit, PA; Rodemann, HP; Wildemann, A | 1 |
| Lichtman, SM; Skirvin, JA | 1 |
| Ames, MM; Krailo, MD; Mares, WL; Mosher, R; Reaman, GH; Reid, JM; Seibel, NL; Wells, RJ; Wiersma, SR | 1 |
| Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Ross, GA; Schätzlein, A; Simpson, AB; Sludden, JA; Twelves, CJ; Wheatley, A; Wilson, P | 1 |
| Beijnen, JH; Holford, NH; Hutson, PR; Mould, DR; Rosing, H; Ross, G; Rowinsky, EK; Russo, M; Schellens, JH; Schiller, JH; ten Bokkel Huinink, WW | 1 |
| Grübner, U; Höffken, K; Hoffmann, A; Kath, R; Merkel, U; Schneider, CP | 1 |
| Burris, HA; Kuhn, JG; Rothenberg, ML; Von Hoff, DD | 1 |
39 review(s) available for topotecan and Neoplasms
| Article | Year |
|---|---|
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Small Molecule Libraries | 2012 |
The long story of camptothecin: From traditional medicine to drugs.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptotheca; Camptothecin; DNA Topoisomerases, Type I; Humans; Medicine, Traditional; Neoplasms; Structure-Activity Relationship | 2017 |
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Taxoids | 2018 |
The design and discovery of topoisomerase I inhibitors as anticancer therapies.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2022 |
Targeting Topoisomerase I in the Era of Precision Medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; DNA Topoisomerases, Type I; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Topoisomerase I Inhibitors; Topotecan | 2019 |
From Lead to Drug Utilizing a Mannich Reaction: The Topotecan Story.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Camptotheca; Cell Proliferation; DNA Topoisomerases, Type I; Humans; Molecular Structure; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2017 |
Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.
Topics: Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Delivery Systems; Humans; Liposomes; Models, Biological; Neoplasms; Patents as Topic; Topotecan | 2016 |
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.
Topics: Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Epirubicin; Etoposide; Humans; Melphalan; Molecular Targeted Therapy; Neoplasms; Topotecan | 2011 |
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Clinical Trials as Topic; Estradiol; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mice; Neoplasms; NF-kappa B; Topotecan; Transcription Factors; Tumor Cells, Cultured | 2011 |
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2002 |
Toxicity patterns of cytotoxic drugs.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Topotecan | 2003 |
ZD9331 in combination with topotecan: phase I and II experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Topotecan | 2003 |
Chemotherapy dosing in the setting of liver dysfunction.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Topotecan | 2005 |
Hypoxia inducible factor-1: a novel target for cancer therapy.
Topics: Benzopyrans; Cell Hypoxia; Heterocyclic Compounds, 4 or More Rings; Humans; Hypoxia-Inducible Factor 1; Microtubules; Models, Biological; Mustard Compounds; Neoplasms; Phenylpropionates; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sirolimus; Topotecan; Tubulin Modulators | 2005 |
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Technology, Pharmaceutical; Tetrahydroisoquinolines; Topotecan | 2007 |
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1995 |
Pharmacokinetics and early clinical studies of selected new drugs.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan | 1993 |
Topoisomerase I inhibitors: topotecan and irenotecan.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1994 |
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
Recent clinical advances with camptothecin analogues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Topotecan | 1995 |
Current perspectives on camptothecins in cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1996 |
Topoisomerase I interactive drugs in children with cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Child; DNA Damage; DNA Topoisomerases, Type I; Humans; Mice; Neoplasms; Topotecan | 1996 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
Clinical development of topoisomerase-interactive drugs.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
[Topoisomerase I inhibitor with potential radiosensitizing effect].
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan | 1997 |
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Clinical status and optimal use of topotecan.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Male; Neoplasms; Safety; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1997 |
DNA topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Topics: Animals; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
An overview of topoisomerase I-targeting agents.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
Topotecan: a new topoisomerase I inhibiting antineoplastic agent.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Economics, Pharmaceutical; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Camptothecins: a review of their development and schedules of administration.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan | 1998 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
Clinical use of topoisomerase I inhibitors in anticancer treatment.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2000 |
The development of camptothecin analogs in childhood cancers.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan | 2002 |
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Confidence Intervals; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Models, Chemical; Neoplasms; Neutropenia; Probability; Topotecan | 2002 |
Clinical trials with the topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Forecasting; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1992 |
95 trial(s) available for topotecan and Neoplasms
| Article | Year |
|---|---|
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptors, Cytoplasmic and Nuclear; Topotecan; Triazoles | 2021 |
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Monitoring; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Thrombocytopenia; Topotecan; Treatment Failure; Treatment Outcome | 2018 |
Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasms; Retrospective Studies; Topotecan | 2019 |
Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
Topics: Administration, Oral; Adult; Aged; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; China; Female; Genotype; Humans; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Polymorphism, Single Nucleotide; Topoisomerase I Inhibitors; Topotecan | 2013 |
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Erlotinib Hydrochloride; Genotype; Humans; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Topotecan | 2014 |
Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.
Topics: Administration, Oral; Aged; Area Under Curve; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Kidney; Kidney Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2015 |
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Molecular Targeted Therapy; Neoplasms; S Phase Cell Cycle Checkpoints; Sirolimus; Texas; Time Factors; Topotecan; Treatment Outcome; Young Adult | 2015 |
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Topics: Adult; Aged; Benzodioxoles; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Female; Hair Follicle; Half-Life; Histones; Humans; Isoquinolines; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan; Young Adult | 2016 |
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Sirolimus; Topotecan; Young Adult | 2017 |
Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Dextrans; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Topotecan | 2008 |
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Salvage Therapy; Topotecan; Treatment Outcome | 2009 |
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Fasting; Female; Food-Drug Interactions; Humans; Intestinal Absorption; Male; Middle Aged; Neoplasms; Therapeutic Equivalency; Topotecan | 2009 |
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 2009 |
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Fatigue; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 2010 |
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Humans; Infant; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Topotecan; Treatment Outcome; Tumor Protein, Translationally-Controlled 1; Young Adult | 2010 |
A phase I study of topotecan and gemcitabine in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 2011 |
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Pemetrexed; Topotecan | 2010 |
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Demography; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2012 |
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Neoplasms; Pilot Projects; Regional Blood Flow; Topoisomerase I Inhibitors; Topotecan | 2011 |
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasms; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Mucositis; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Topotecan; Transplantation, Autologous; Treatment Outcome | 2011 |
A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Risk Factors; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Transplantation, Autologous | 2012 |
Phase I studies of nogitecan hydrochloride for Japanese.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Japan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2002 |
Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Feces; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 2002 |
Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 2002 |
Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Synergism; Female; Fever; Humans; Infections; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Patient Dropouts; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Cohort Studies; Confidence Intervals; Female; Humans; Infusions, Intravenous; Male; Neoplasms; Pilot Projects; Topotecan | 2003 |
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Cisplatin; Erythrocytes; Female; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Prospective Studies; Sex Factors; Topotecan | 2003 |
ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2003 |
Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2003 |
ZD9331 in combination with topotecan: phase I and II experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Topotecan | 2003 |
Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Salvage Therapy; Topotecan | 2004 |
Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Salvage Therapy; Sampling Studies; Sensitivity and Specificity; Topotecan; Treatment Outcome | 2004 |
Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Taxoids; Topotecan; Treatment Outcome | 2004 |
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 2004 |
Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome | 2004 |
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Topotecan | 2005 |
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Topotecan | 2005 |
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Humans; Middle Aged; Neoplasms; Topotecan | 2005 |
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan; Treatment Outcome | 2006 |
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome | 2005 |
Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Topics: Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Ovarian Neoplasms; Polyethylene Glycols; Topotecan | 2005 |
Phase I study of docetaxel and topotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Cells; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Taxoids; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 2006 |
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Topics: Acridines; Administration, Oral; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cohort Studies; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Research Design; Tetrahydroisoquinolines; Topotecan | 2007 |
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States | 1995 |
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 1995 |
Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
Topics: Adult; Aged; Camptothecin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Recombinant Proteins; Structure-Activity Relationship; Topotecan | 1993 |
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Infusions, Intravenous; Linear Models; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Remission Induction; Topotecan | 1995 |
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 1994 |
Preclinical and phase I trials of topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Clinical, pharmacokinetic and biological studies of topotecan.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutrophils; Topotecan | 1994 |
Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.
Topics: Adolescent; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Lactones; Leukocyte Count; Male; Neoplasms; Neutrophils; Platelet Count; Topotecan | 1994 |
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 1994 |
Phase I study of topotecan for pediatric patients with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Half-Life; Hematopoiesis; Humans; Infusions, Intravenous; Male; Neoplasms; Topotecan; Treatment Outcome | 1994 |
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Diseases; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 1994 |
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Topotecan | 1993 |
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Time Factors; Topotecan | 1993 |
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Hematopoiesis; Humans; Male; Neoplasms; Topotecan | 1996 |
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Reference Values; Topotecan | 1996 |
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan; Tumor Cells, Cultured | 1996 |
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 1997 |
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 1997 |
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Topotecan | 1998 |
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Topotecan | 1998 |
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1998 |
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 1998 |
A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1997 |
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Topics: Adult; Aged; Antineoplastic Agents; DNA Topoisomerases, Type I; Female; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 1997 |
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Headache; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Skin Diseases; Thrombocytopenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome; Vomiting | 1996 |
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Topotecan; Treatment Outcome | 1998 |
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukopenia; Middle Aged; Neoplasms; Topotecan | 1999 |
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome | 1999 |
Topotecan lacks third space sequestration.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ascitic Fluid; Cisplatin; Dexamethasone; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Ondansetron; Pleural Effusion; Topotecan; Vomiting | 2000 |
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 2000 |
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Paclitaxel; Platelet Count; Recombinant Proteins; Taxoids; Topotecan | 2000 |
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Neoplasms; Ranitidine; Topotecan | 2000 |
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 2000 |
Gender-dependent pharmacokinetics of topotecan in adult patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboxylic Acids; Cisplatin; Dose-Response Relationship, Drug; Female; Hematocrit; Humans; Infusions, Intravenous; Lactones; Male; Neoplasms; Sex Factors; Topotecan | 2000 |
Phase I study of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Topotecan | 2000 |
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Topotecan | 2001 |
Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan; Treatment Outcome | 2001 |
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Phase I clinical trial of weekly combined topotecan and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Topotecan | 2001 |
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2001 |
Phase I study of combination topotecan and carboplatin in pediatric solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Likelihood Functions; Male; Maximum Tolerated Dose; Neoplasms; Salvage Therapy; Topotecan | 2002 |
Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Rhabdomyosarcoma; Salvage Therapy; Topotecan; Treatment Outcome | 2002 |
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Survival Rate; Topotecan | 2002 |
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Disease Progression; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Ifosfamide; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Recurrence; Topotecan | 2002 |
91 other study(ies) available for topotecan and Neoplasms
| Article | Year |
|---|---|
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.
Topics: Acridines; Aminacrine; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Models, Chemical; Neoplasms; RNA, Small Interfering | 2009 |
Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Drug Discovery; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Conformation; Naphthyridines; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Transplantation, Heterologous | 2009 |
Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1,2-c]quinoline derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; G1 Phase; Humans; Neoplasms; Quinolines | 2011 |
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil | 2017 |
Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Neoplasms; Piperazine; Piperazines; Sulfones | 2017 |
Structure-Based Drug Design and Identification of H
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Drug Design; Humans; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasms; Sepsis; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzophenanthridines; Binding Sites; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Molecular Dynamics Simulation; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2021 |
Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation.
Topics: Animals; Mice; Neoplasms; Ribosomal Proteins; Topoisomerase I Inhibitors; Topotecan | 2022 |
[Elucidation of the Mechanism of Topotecan-induced Antitumor Immune Activation].
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Immunotherapy; Mice; Neoplasms; Topotecan | 2022 |
Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.
Topics: Ataxia Telangiectasia; DNA; DNA Repair; DNA-Activated Protein Kinase; Endothelial Cells; Humans; Neoplasms; Spheroids, Cellular; Temozolomide; Topotecan; Trabectedin | 2023 |
Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin.
Topics: A549 Cells; Animals; Carbamates; Cell Movement; Cisplatin; Dipeptides; DNA Methylation; Epigenesis, Genetic; Ferroptosis; Heterografts; Histones; Humans; Lapatinib; Mice; Neoplasm Invasiveness; Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Pyridines; Topotecan | 2020 |
Identification of key genes and pathways associated with topotecan treatment using multiple bioinformatics tools.
Topics: Animals; Cell Line, Tumor; Computational Biology; Cyclin-Dependent Kinase Inhibitor p21; Enhancer of Zeste Homolog 2 Protein; Humans; Mice; Neoplasms; Prognosis; Protein Interaction Maps; Topotecan | 2020 |
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cisplatin; Codon; Epigenesis, Genetic; Gain of Function Mutation; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Mice, SCID; Models, Biological; Mutant Proteins; Mutation; Neoplasms; NF-kappa B; Nucleotide Motifs; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Isoforms; Sulfonamides; Topotecan; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2020 |
Engineered liposomes bearing camptothecin analogue for tumour targeting:
Topics: Animals; Camptothecin; Liposomes; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2021 |
Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
Topics: Animals; Antigen-Presenting Cells; Antigens, Ly; Cancer Vaccines; CD11c Antigen; Cell Proliferation; Coculture Techniques; Combined Modality Therapy; Dendritic Cells; Humans; Immunity, Innate; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Mice; Neoplasms; Receptors, IgG; T-Lymphocytes; Topoisomerase I Inhibitors; Topotecan; Tumor Microenvironment | 2021 |
Topotecan-loaded thermosensitive nanocargo for tumor therapy: In vitro and in vivo analyses.
Topics: Animals; Drug Carriers; Mice; Mice, Nude; Nanoparticles; Neoplasms; Particle Size; Rats; Topotecan | 2021 |
Identification of Angiogenesis Inhibitors Using a Co-culture Cell Model in a High-Content and High-Throughput Screening Platform.
Topics: Angiogenesis Inhibitors; Bortezomib; Cell Line, Transformed; Coculture Techniques; Docetaxel; Drug Evaluation, Preclinical; Endothelium, Vascular; High-Throughput Screening Assays; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mesenchymal Stem Cells; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Telomerase; Topotecan | 2018 |
Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells.
Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Topoisomerases, Type I; Humans; Neoplasms; Synthetic Lethal Mutations; Topotecan | 2018 |
Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.
Topics: Animals; Antineoplastic Agents; Coordination Complexes; Drug Delivery Systems; Drug Liberation; Fever; Gadolinium; High-Intensity Focused Ultrasound Ablation; Humans; Hyperthermia, Induced; Indicators and Reagents; Lipids; Liposomes; Magnetic Resonance Imaging; Mice, Inbred BALB C; Neoplasms; Optical Imaging; Temperature; Tissue Distribution; Topotecan; Tumor Microenvironment | 2018 |
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.
Topics: Adult; Aged; Benzimidazoles; Cachexia; Female; Humans; Male; Middle Aged; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prospective Studies; Tomography, X-Ray Computed; Topoisomerase Inhibitors; Topotecan; Weight Loss | 2018 |
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Identification of cisplatin sensitizers through high-throughput combinatorial screening.
Topics: Antimony Potassium Tartrate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; High-Throughput Screening Assays; Humans; Neoplasms; Topotecan; Tumor Cells, Cultured | 2018 |
Topotecan effect on the structure of normal and cancer plasma membrane lipid models: A multi-model approach.
Topics: Animals; Cell Membrane; Cell Membrane Permeability; Dimyristoylphosphatidylcholine; Humans; Membranes, Artificial; Models, Biological; Molecular Structure; Neoplasms; Phosphatidylcholines; Phosphatidylserines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2018 |
Improved In vivo Effect of Chrysin as an Absorption Enhancer Via the Preparation of Ternary Solid Dispersion with Brij®L4 and Aminoclay.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Availability; Clay; Detergents; Drug Compounding; Drug Evaluation, Preclinical; Flavonoids; HT29 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Male; Neoplasms; Polidocanol; Rats; Rats, Sprague-Dawley; Solubility; Topotecan; Water | 2019 |
Structure-Activity Relationships of Cytotoxic Lactones as Inhibitors and Mechanisms of Action.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Sesquiterpenes; Structural Homology, Protein; Structure-Activity Relationship; Topotecan; Tubulin; Tubulin Modulators | 2020 |
Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myb; Sesquiterpenes; Structure-Activity Relationship; Topotecan | 2020 |
Hypoxia inducible factor 1 inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; Digoxin; Flavonoids; Humans; Hypoxia-Inducible Factor 1; Mustard Compounds; Neoplasms; Oligonucleotides; Phenylpropionates; Polyethylene Glycols; Topotecan | 2019 |
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Coronary Vessels; Doxorubicin; Female; Humans; Kidney; Liver; Mice; Mice, Nude; Mitoxantrone; Myocardium; Neoplasms; Neovascularization, Pathologic; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2013 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Multifunctional enveloped mesoporous silica nanoparticles for subcellular co-delivery of drug and therapeutic peptide.
Topics: Cell Line, Tumor; Drug Delivery Systems; Endocytosis; Humans; Microscopy, Confocal; Nanoparticles; Neoplasms; Organophosphorus Compounds; Peptides; Silicon Dioxide; Topotecan; Tumor Microenvironment | 2014 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude of Health Personnel; Carboplatin; Child; Child, Preschool; Curriculum; Databases, Factual; Education, Medical; Enzyme Inhibitors; Etoposide; Europe; Female; General Surgery; Germany; Hospitals, University; Humans; Ifosfamide; Lung Neoplasms; Male; Medical History Taking; Mesothelioma; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Neurons; Muscular Atrophy; Neoplasms; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Physical Examination; Quality Improvement; Spinal Cord Injuries; Topotecan; Universities; World Health Organization; Young Adult | 2014 |
Topotecan-loaded mesoporous silica nanoparticles for reversing multi-drug resistance by synergetic chemoradiotherapy.
Topics: Cell Survival; DNA Damage; Drug Carriers; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; Nanoparticles; Neoplasms; Polyethylene Glycols; Porosity; Radiation, Ionizing; Silicon Dioxide; Topoisomerase I Inhibitors; Topotecan | 2015 |
[DNA topoisomerase I--targeting drugs].
Topics: Camptothecin; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2015 |
Chemical profiling of the genome with anti-cancer drugs defines target specificities.
Topics: Aclarubicin; Antineoplastic Agents; Cell Line, Tumor; Chromatin; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genome, Human; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Organ Specificity; Protein Transport; Structure-Activity Relationship; Topoisomerase Inhibitors; Topotecan | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
Topics: Animals; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Emulsions; Mice; Nanoparticles; Neoplasms; Particle Size; Topotecan | 2016 |
DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Dendritic Cells; DNA, Neoplasm; Exosomes; Female; Immunity, Innate; Lymphocyte Activation; Membrane Proteins; Mice; Neoplasms; Signal Transduction; Topoisomerase I Inhibitors; Topotecan | 2017 |
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
Topics: Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mitoxantrone; Molecular Docking Simulation; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan | 2017 |
Antitumor efficacy testing in rodents.
Topics: Animals; Antineoplastic Agents; Biological Availability; Dacarbazine; Data Interpretation, Statistical; Drug Approval; Drug Design; Drug Screening Assays, Antitumor; Drugs, Investigational; Endpoint Determination; Humans; Kaplan-Meier Estimate; Mice; Neoplasms; Pharmaceutical Vehicles; Random Allocation; Rats; Research Design; Rodentia; Sample Size; Tamoxifen; Temozolomide; Topotecan; Transplantation, Heterologous; United States | 2008 |
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Inhibitory Concentration 50; Methotrexate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Sunitinib; Time Factors; Topotecan; Transfection; Up-Regulation; Vincristine | 2009 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
Initial testing of topotecan by the pediatric preclinical testing program.
Topics: Antineoplastic Agents; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Models, Theoretical; Neoplasms; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Drug Synergism; Humans; Liposomes; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Vincristine | 2010 |
Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.
Topics: Antineoplastic Agents; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Neoplasms; Organoplatinum Compounds; Organoselenium Compounds; Oxaliplatin; Paclitaxel; RNA Interference; Taxoids; Topotecan | 2010 |
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; fas Receptor; Female; Histocompatibility Antigens Class I; Humans; Immunotherapy; Interleukin-18; Mice; Mice, Inbred C57BL; Neoplasms; Paclitaxel; T-Lymphocytes; Time Factors; Topotecan; Up-Regulation | 2011 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Embryo, Mammalian; Fibroblasts; Humans; Mice; Mice, Knockout; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Topotecan | 2012 |
Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma, Lewis Lung; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Half-Life; Hand-Foot Syndrome; Humans; Injections, Intravenous; Leukemia L1210; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Rats; Rats, Wistar; Skin; Skin Diseases; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Floxuridine; Gemcitabine; High-Throughput Screening Assays; Humans; Methotrexate; Mitomycin; Models, Animal; Neoplasms; Topotecan | 2012 |
Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Culture Media; Glutathione; Gold; Humans; Metal Nanoparticles; Mice; Microscopy, Confocal; Neoplasms; Topotecan | 2012 |
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Topics: Animals; Biopsy; Cell Line, Tumor; Clinical Trials as Topic; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Immunoassay; Isoquinolines; Leukocytes, Mononuclear; Mice; Neoplasms; Poly(ADP-ribose) Polymerases; Time Factors; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.
Topics: Algorithms; Ammonium Sulfate; Animals; Antineoplastic Agents; Drug Carriers; Drug Compounding; Drug Stability; Humans; Indicators and Reagents; Lactones; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms; Topotecan; Tumor Cells, Cultured | 2002 |
Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Cell Survival; Chromosome Aberrations; Colonic Neoplasms; Fibroblasts; Glioblastoma; Humans; Lymphocytes; Metaphase; Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topotecan; Tumor Cells, Cultured | 2002 |
Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cricetinae; DNA; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Haplorhini; Humans; Lung; Lymphocytes; Macromolecular Substances; Mice; Mice, Nude; Neoplasms; Nucleic Acid Synthesis Inhibitors; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Subunits; RNA Polymerase II; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Topoisomerase I Inhibitors; Topotecan; Transcription, Genetic; Xenograft Model Antitumor Assays | 2003 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 2003 |
[Topotecan for pediatric patients with resistant and recurrent solid tumors].
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infant; Male; Neoplasm Staging; Neoplasms; Remission Induction; Retrospective Studies; Topotecan | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
Topics: Anemia; Antineoplastic Agents; Confidence Intervals; Cost Savings; Cross-Cultural Comparison; Drug Utilization; Erythropoietin; Fee-for-Service Plans; Female; Health Expenditures; Hemoglobinometry; Humans; Male; Managed Care Programs; Medical Oncology; Neoplasms; Odds Ratio; Ovarian Neoplasms; Practice Guidelines as Topic; Practice Patterns, Physicians'; Regression Analysis; Topotecan; United States | 2004 |
A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials, Phase I as Topic; Computer Simulation; Drug Therapy, Combination; Humans; Maximum Tolerated Dose; Neoplasms; Research Design; Statistics, Nonparametric; Topotecan | 2004 |
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2004 |
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; ErbB Receptors; Gene Expression Regulation; Humans; JNK Mitogen-Activated Protein Kinases; Neoplasms; Proto-Oncogene Proteins c-jun; Recombinant Fusion Proteins; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
New drugs target hypoxia response in tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drugs, Investigational; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Nuclear Proteins; Phenylpropionates; Topotecan; Transcription Factors; Transplantation, Heterologous | 2005 |
Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Etoposide; Genetic Vectors; Green Fluorescent Proteins; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Isoquinolines; Neoplasms; Oxygen; Sequence Deletion; Topotecan; Transcriptional Activation | 2006 |
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Comet Assay; DNA Damage; DNA Fragmentation; DNA, Complementary; Glioma; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Norepinephrine Plasma Membrane Transport Proteins; Time Factors; Topotecan; Transfection | 2005 |
Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan.
Topics: Antineoplastic Agents; CA-125 Antigen; Humans; Infusions, Intravenous; Neoplasms; Topotecan | 2006 |
New Agents in Clinical Oncology. 24 November 2006, London, UK.
Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Combined Modality Therapy; Enzyme Inhibitors; Humans; Medical Oncology; Neoplasms; Norepinephrine Plasma Membrane Transport Proteins; Poly(ADP-ribose) Polymerase Inhibitors; Proteomics; Stilbenes; Thioredoxins; Topotecan | 2007 |
Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.
Topics: Adenoviridae; Animals; Base Sequence; Cell Line; Defective Viruses; DNA Primers; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; In Vitro Techniques; Liver; Mice; Mice, Inbred BALB C; Neoplasms; Rats; Rats, Inbred Lew; Topoisomerase I Inhibitors; Topotecan; Transduction, Genetic | 2007 |
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
Topics: Amino Acid Sequence; Antibodies; Antibody Affinity; Cell Line, Tumor; Cell Survival; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation; Humans; Liposomes; Molecular Sequence Data; Mutation; Nanoparticles; Neoplasms; Sequence Alignment; Solubility; Topotecan | 2007 |
Population pharmacokinetic analysis of topotecan in pediatric cancer patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Female; Humans; Infant; Male; Models, Biological; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2007 |
Topotecan treatment and its toxic effects on hematologic parameters and trace elements.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Dietary Supplements; Erythrocytes; Hemoglobins; Humans; Neoplasms; Rabbits; Time Factors; Topotecan; Trace Elements | 2008 |
Clinical trials referral resource. Trials of topotecan.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Female; Humans; Male; Neoplasms; Topotecan | 1995 |
Topoisomerase I inhibition: a new target or new missiles?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Design; Drug Synergism; Humans; Irinotecan; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1995 |
Clinical trials referral resource. Clinical trials with topotecan.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Humans; Neoplasms; Topotecan | 1993 |
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Combined Modality Therapy; Fibroblasts; Humans; Melanoma; Neoplasms; Radiation Dosage; Radiation Tolerance; Time Factors; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; DNA Fragmentation; DNA, Neoplasm; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan | 1997 |
Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Adhesion; Chromatin; Fibronectins; HeLa Cells; Humans; Methacrylates; Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Topotecan; Tumor Cells, Cultured | 1997 |
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Topics: Camptothecin; Cell Cycle; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunohistochemistry; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1997 |
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1997 |
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1998 |
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Biological Availability; Child; Child, Preschool; Female; Humans; Infant; Injections, Intravenous; Male; Neoplasm Recurrence, Local; Neoplasms; Topotecan | 1999 |
Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Topics: Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Feces; Humans; Neoplasms; Reproducibility of Results; Spectrometry, Fluorescence; Topotecan | 1999 |
Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Dihydropyridines; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Neoplasms; Phenotype; Topotecan; Tumor Cells, Cultured | 1999 |
Population pharmacokinetic model for topotecan derived from phase I clinical trials.
Topics: Aged; Antineoplastic Agents; Body Constitution; Clinical Trials, Phase I as Topic; Female; Humans; Kidney; Male; Middle Aged; Models, Theoretical; Neoplasms; Topotecan | 2000 |
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Docetaxel; Drug Interactions; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Cisplatin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Neoplasms; Patient Selection; Retrospective Studies; Topotecan | 2000 |
Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorometry; Humans; Irinotecan; Neoplasms; Topotecan; Tumor Cells, Cultured | 2000 |
Pharmacodynamic model of topotecan-induced time course of neutropenia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Disease Models, Animal; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Neutrophils; Recombinant Proteins; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2001 |
Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Combined Modality Therapy; Enzyme Inhibitors; Fibroblasts; Humans; Neoplasms; Radiation, Ionizing; Time Factors; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2002 |